Skip to main content
Telix Pharmaceuticals Ltd logo

Telix Pharmaceuticals Ltd — Investor Relations & Filings

Ticker · TLX ISIN · AU000000TLX2 ASX Manufacturing
Open in API
Filings indexed 989 across all filing types
Latest filing 2024-07-29 Capital/Financing Update
Country US United States of America
Listing ASX TLX

About Telix Pharmaceuticals Ltd

https://telixpharma.com/

Telix Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals, an approach known as 'theranostics'. The company utilizes targeted radiation to both image and treat various forms of cancer. Its extensive clinical pipeline and portfolio address key areas in oncology, including urologic (prostate and kidney), neurologic (glioma), and musculoskeletal cancers, as well as applications in bone marrow conditioning. Telix has secured global regulatory approvals for its prostate cancer imaging agent and supports its products with a robust global supply, manufacturing, and distribution network. The company is actively engaged in numerous clinical trials worldwide to expand its theranostic platform.

Recent filings

Filing Released Lang Actions
Convertible Bond Cleansing Notice 283 pages 2.9MB
Capital/Financing Update Classification · 95% confidence The document is a detailed notice under section 708A(12C)(e) of the Corporations Act 2001 (Cth) related to the pricing and offering of convertible notes by Telix Pharmaceuticals Limited. It includes an attached offering circular with full terms and conditions of the notes, details on the effect of the offering on the company's capital structure, and compliance with disclosure obligations. The document is not an annual or interim financial report, nor is it a transcript, management report, or governance document. It is a formal announcement regarding a capital raising via convertible notes, including detailed financing terms and conditions. This fits the definition of a Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains substantive information about the financing, not merely an announcement of a report or a certification. Therefore, the correct classification is CAP with high confidence.
2024-07-29 English
Telix Completes A$650 Million of Convertible Bonds 1
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement by Telix Pharmaceuticals Limited dated 30 July 2024, announcing the completion of a A$650 million convertible bonds issuance. The text focuses on the completion of a financing activity, mentioning the convertible notes issuance, listing on the Singapore Exchange, and the role of J.P. Morgan Securities as Sole Manager. There are no financial statements or detailed financial performance data, so it is not an Annual Report or Interim Report. The document is not a report publication announcement since it contains substantive information about the financing completion. It is clearly an update on capital raising and financing activities. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is 3276 characters, which is consistent with an announcement rather than a full report. Confidence is high given the clear content and context.
2024-07-29 English
Appendix 3G 18 pages 413.6KB
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Appendix 3G Notification of issue, conversion or payment up of unquoted equity securities' and references specific ASX listing rules (3.10.3A, 3.10.3B, 3.10.3C, 3.10.3D). It is a detailed form used to notify the Australian Securities Exchange (ASX) about the issuance or conversion of unquoted equity securities. The content includes entity details, type of securities issued, dates, and other regulatory compliance information related to securities issuance. This type of document is a regulatory announcement related to capital changes, specifically the issuance or conversion of securities. It is not a financial report, earnings release, or management discussion. It is also not a report publication announcement or certification. The document fits the definition of a Share Issue/Capital Change announcement, which covers new share issues or other capital changes. Therefore, the correct classification is 'SHA' (Share Issue/Capital Change). The document length and detail support a high confidence score.
2024-07-29 English
Becoming a substantial holder 39 pages 1.8MB
Major Shareholding Notification Classification · 100% confidence The document is a Form 603 filed under the Corporations Act 2001 Section 671B, titled 'Notice of initial substantial holder.' It details the substantial shareholding of JPMorgan Chase & Co. and its affiliates in Telix Pharmaceuticals Ltd, including voting power, relevant interests, associates, and transaction details. This form is a regulatory notification of a major shareholding crossing a threshold, not a financial report, management announcement, or other types of filings. The document is lengthy and detailed but is clearly a major shareholding notification as per Australian regulatory requirements.
2024-07-28 English
Becoming a substantial holder 34 pages 3.3MB
Major Shareholding Notification Classification · 100% confidence The document is a Form 603 filed under the Corporations Act 2001, titled 'Notice of initial substantial holder'. It details the substantial shareholding of State Street Corporation and its subsidiaries in Telix Pharmaceuticals Limited, including voting power, relevant interests, registered holders, consideration paid, and associates. This form is a regulatory notification about a change in significant share ownership levels, specifically the initial substantial holder notice. It is not a financial report, earnings release, or management report. It fits the definition of a Major Shareholding Notification (MRQ). The document length and content confirm it is the actual notification, not just an announcement or certification. Therefore, the correct classification is MRQ with high confidence.
2024-07-25 English
Telix Successfully Prices A$650M Convertible Bonds 3 pages 153.5KB
Capital/Financing Update Classification · 100% confidence The document is an ASX announcement from Telix Pharmaceuticals Limited dated 24 July 2024. It details the successful pricing of A$650 million convertible bonds, including terms such as interest rate, maturity, conversion price, and intended use of proceeds. The document is focused on a financing event, specifically the issuance of convertible bonds, and includes detailed terms and conditions of the offering. There is no indication that this is a full financial report, earnings release, or management discussion. The document is not a regulatory filing or a report publication announcement but a direct update on a capital raising activity. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (over 10,000 characters) and detailed content support this classification with high confidence.
2024-07-23 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.